<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653458</url>
  </required_header>
  <id_info>
    <org_study_id>ODO-P2-159</org_study_id>
    <nct_id>NCT00653458</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, Cross Over Bioavailability Study of Kali's Ondansetron ODT 8 mg With That of GlaxoSmithKine's Zofran ODT 8 mg in Healthy Adult Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algorithme Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single-dose bioavailability of Kali's Ondansetron ODt 8 mg with that of
      GlaxoSmithKine's Zofran 8 mg under fed conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Kali formulated products under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received GlaxoSmithKline's formulated products under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>ODT, 8 mg, single-dose, fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Zofran ODT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran</intervention_name>
    <description>ODT, 8 mg, single-dose, under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Ondansetron ODT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects meeting all of the following criteria may be included in the study

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements as evidenced by the informed consent from duly signed by the
             subject.

          -  Males and females aged from 18 to 50 years with a body mass index (BMI) within 19-30;
             demographic data (sex, age, ethnic group, body weight, height and smoking habits) will
             be recorded and reported in the final report.

          -  Clinical laboratory values within the laboratory's stated normal range; if not within
             this range, they must be without ant clinical significance and must be recorded as
             such in the CRF ( laboratory tests are presented in section 7.1.3)

          -  Healthy according to the laboratory results and physical examination.

          -  Normal cardiovascular function according to the to ECG.

          -  Non or ex-smokers.

        Exclusion Criteria:

          -  Significant history of hypersensitivity to ondansetron or any related products as well
             as severe hypersensitivity reactions (like angioedema) to any drugs.

          -  Presence or history of significant gastrointestinal, liver or kidney disease, or any
             other conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects.

          -  Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic,
             psychiatric, endocrine, immunologic or dermatologic disease.

          -  Females who pregnant, lactating or are likely to become pregnant during the study
             phases.

          -  Females or childbearing potential who refuse to use an acceptable contraceptive
             regimen throughout the study.

          -  Positive pregnancy test before and during the study.

          -  Maintenance therapy with any drug, or significant history of drug dependency, alcohol
             abuse (&gt;3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or
             serious psychological disease.

          -  Any clinically significant illness in the previous 28 days before day 1 of this study.

          -  Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all
             barbiturates, corticosteroids, phenylhydantoins, etc.)

          -  Participation in another clinical trial in the previous 28 days before day 1 of this
             study.

          -  Donation of 500 mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies,
             etc.) in the previous 56 days before day 1 of this study.

          -  Positive urine screenings of drugs of abuse (drug names are presented in section
             7.1.4).

          -  Positive results to HIV, HBsAg or anti-HCV tests.

          -  History of fainting upon blood sampling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Aumais</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algotithme Pharma Inc</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 10, 2008</last_update_submitted>
  <last_update_submitted_qc>April 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr.Alfred Elvin/ Diector Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>Ondansetron ODT</keyword>
  <keyword>fed</keyword>
  <keyword>To determine bioequivalence under fed conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

